ArticlePloS one2026
Prevalence and associated factors of non-variceal upper gastrointestinal bleeding among cirrhotic patients with upper gastrointestinal bleeding on follow-up at a Tertiary Hospital in Ethiopia.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver cirrhosis is a major cause of morbidity and mortality worldwide. Non-variceal upper gastrointestinal bleeding (NVUIGB) accounts for 24-42% of bleeding episodes in cirrhotic patients and carries a mortality rate of 15-30%. Understanding its prevalence and associated factors is critical for prevention and improved outcomes. This study assessed the prevalence and predictors of NVUGIB among cirrhotic patients with upper gastrointestinal bleeding at a tertiary hospital in Addis Ababa, Ethiopia.
methodsA hospital based cross-sectional study was conducted from December 2020 to December 2023. A total of 234 patients were included in the study. The collected data were analyzed using Statistical Package for Social Sciences (SPSS) version 26.0. Bivariable and multivariable logistic regression was used to assess association between dependent and independent variables. Adjusted odds ratio with a 95% confidence interval was used to estimate the strength of association and level of statistical significance was declared at p value <0.05.
resultsThe prevalence of non-variceal upper gastrointestinal bleeding was 31.6% (95% CI: 26.0-37.8). with a mean (±SD) age of 39 ± 14 years. Independent predictors of non-variceal upper gastrointestinal bleeding included longer duration of cirrhosis (AOR = 1.01, 95% CI: 1.001-1.019, p = 0.03) and Human Immunodeficiency Virus (HIV) (AOR = 51.72, 95% CI: 5.65-471.8, p < 0.001). Lower odds of non-variceal upper gastrointestinal bleeding were observed in older patients (AOR = 0.96, 95% CI: 0.93-0.99, p = 0.007), those with hepatitis C virus (AOR = 0.12, 95% CI: 0.05-0.66, p = 0.009) or schistosomiasis (AOR = 0.03, 95% CI: 0.006-0.19, p < 0.001) as the cause of cirrhosis, prior beta-blocker use (AOR = 0.32, 95% CI: 0.14-0.70, p = 0.005), and higher international normalized ratio (AOR = 0.57, 95% CI: 0.36-0.89, p = 0.014). Non-variceal upper gastrointestinal bleeding patients also had lower systolic blood pressure at presentation (AOR = 0.97, 95% CI: 0.95-0.99, p = 0.010) but required fewer blood product transfusions (AOR = 0.25, 95% CI: 0.08-0.71, p = 0.009).
conclusionNon-variceal upper gastrointestinal bleeding accounted for nearly one-third (31.6%) of bleeding cases among cirrhosis patients with upper gastrointestinal bleeding. It was significantly associated with longer duration of cirrhosis, younger age, and the presence of comorbidities such as HIV. Targeted screening and preventive measures for high-risk patients may reduce the burden of NVUGIB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.